LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 ...
LONDON--(BUSINESS WIRE)-- GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old ...
MISSISSAUGA, ON, June 2, 2026 /CNW/ - GSK announced today that Health Canada has approved Nucala (mepolizumab) as an add-on maintenance treatment in adult patients with COPD characterized by raised ...
Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection. Nucala injection ...
GlaxoSmithKline’s Nucala is facing an uphill climb in its battle for supremacy in severe asthma. On the hunt for a leg up, GSK is looking to real-world studies for a competitive advantage in Nucala’s ...
First IL-5 therapy approved as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps to target eosinophilic inflammation Fourth indication for mepolizumab in the US ...
Nucala is the only approved biologic showing efficacy for up to two years in a wide spectrum of COPD patients with raised blood eosinophils inadequately controlled by the combination of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results